Accepted for/Published in: Interactive Journal of Medical Research
Date Submitted: Oct 24, 2025
Date Accepted: Apr 20, 2026
Value of Blood Count-Derived Inflammatory Markers for Evaluating Psoriasis Severity: A Pilot Study
ABSTRACT
Background:
Objective indicators for evaluating and monitoring psoriasis is needed.
Objective:
This study hopes to verify the clinical value of blood-count-derived inflammatory markers in the evaluation psoriasis, and explore application value in combining with pro-inflammatory factors.
Methods:
ROC curve and binary logistic regression were used to evaluate the predictive power of blood-count-derived inflammatory markers and the consistency with Psoriasis Area Severity Index (PASI) in distinguishing severity. The association with PASI and the combination with pro-inflammatory factor of the blood-count-derived inflammatory markers was analyzed.
Results:
The area under the curve showed Systemic Immune Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Aggregate Index of Systemic Inflammations (AISI) were effective in reflexing the activity of psoriasis and showed advantages in psoriasis patients with arthritis and cardiovascular metabolic diseases. The comprehensive test showed the good consistency of SIRI and PASI in distinguishing the severity. SII, SIRI and AISI were significantly correlated with IL-6 in lesions, and the combination with IL-6, IL-1 and IL-17 were also significantly correlated with PASI.
Conclusions:
The blood-count-derived inflammatory markers could better reflect the inflammation of patients with psoriasis. SII, SIRI and AISI have important clinical significance in evaluating disease activity. Combinating with proinflammatory factors showed advantage.
Citation
Per the author's request the PDF is not available.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.